MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, INBX had $37,437K increase in cash & cash equivalents over the period. -$38,026K in free cash flow.

Cash Flow Overview

Change in Cash
$37,437K
Free Cash flow
-$38,026K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from the issuance of de...
    • Accounts payable
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Accrued expenses
    • Prepaid expenses and other curre...
    • Non-cash lease expense

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-33,441 -32,834 -35,256 -71,965
Depreciation and amortization
537 564 583 1,336
Accretion of debt discount and non-cash interest expense
732 642 638 1,159
Stock-based compensation expense
2,653 2,743 3,175 5,220
Non-cash lease expense
-1,803 --
Non-cash gain on transaction with acquirer
-0 --
Loss on disposal of property and equipment
--9 -3 -
Non-cash gain on transaction with acquirer
--0 0
Non-cash lease expense
-851 -456 878
Accounts receivable
0 46 -127 -119
Other receivables
9 -706 -3 689
Receivables from related parties
0 0 0 -23
Prepaid expenses and other current assets
1,063 -423 -25 -952
Other non-current assets
0 0 22 -22
Accounts payable
2,818 -829 -1,519 -953
Accrued expenses
-10,187 -1,434 -1,515 -1,412
Operating lease liability
-549 -535 -522 -538
Net cash used in operating activities
-38,026 -30,122 -33,824 -65,848
Purchase of property and equipment
0 0 10 21
Proceeds from the sale of property and equipment
-0 3 -
Net cash used in investing activities
0 0 -7 -21
Proceeds from the issuance of debt
74,992 0 0 99,965
Payment of third-party fees associated with debt
-125 --
Payment of fees associated with debt
-125 -0 125
Proceeds from the exercise of stock options
471 1,254 352 0
Net cash provided by financing activities
75,463 1,254 352 99,840
Net increase in cash and cash equivalents
37,437 -28,868 -33,479 33,971
Cash and cash equivalents at beginning of period
124,220 153,088 152,596 -
Cash and cash equivalents at end of period
161,657 124,220 153,088 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from theissuance of debt$74,992K Proceeds from theexercise of stock options$471K Net cash provided byfinancing activities$75,463K Net increase in cashand cash...$37,437K Canceled cashflow$38,026K Accounts payable$2,818K Stock-based compensationexpense$2,653K Accretion of debt discountand non-cash...$732K Depreciation andamortization$537K Net cash used inoperating activities-$38,026K Canceled cashflow$6,740K Net loss-$33,441K Accrued expenses-$10,187K Prepaid expenses andother current assets$1,063K Non-cash lease expense-$851K

Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences, Inc. (INBX)